MedTrace Logo

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT03920631 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-03-23

No results posted yet for this study

Summary

The purpose of this study is to find out if microtransplantation (MST) in combination with nivolumab is safe and effective in patients with relapsed or refractory B cell lymphomas.

Conditions

  • B Cell Lymphomas

Interventions

DRUG

Nivolumab

Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

BIOLOGICAL

Microtransplantation

HLA-mismatched peripheral blood stem cells

Sponsors & Collaborators

  • Ahmed Galal, MD

    lead OTHER

Principal Investigators

  • Ahmed Galal, MD · Duke Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2023-03-15
Completion
2023-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920631 on ClinicalTrials.gov